BiomX Issues Statement Regarding Recent Common Stock Trading Activity

Core Viewpoint - BiomX Inc. has issued a statement addressing unusual market activity in its common stock, indicating no material developments have occurred that have not been previously disclosed [1][2]. Company Overview - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies aimed at targeting and eliminating specific pathogenic bacteria [3]. - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to create customized phage compositions against proprietary bacterial targets [3].